This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cosman F et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353: 566–575
Rittmaster RS et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85: 2129–2134
Deftos LJ (2005) Treatment of Paget's disease—taming the wild osteoclast. N Engl J Med 353: 872–875
Lindsay et al. (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164: 2024–2030
Acknowledgements
The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Deftos, L. Combination therapy for osteoporosis: a counter-regulatory conundrum. Nat Rev Rheumatol 2, 64–65 (2006). https://doi.org/10.1038/ncprheum0096
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0096